CN108220241B - Erythrocyte progenitor cell serum-free medium and use method thereof - Google Patents
Erythrocyte progenitor cell serum-free medium and use method thereof Download PDFInfo
- Publication number
- CN108220241B CN108220241B CN201711458658.7A CN201711458658A CN108220241B CN 108220241 B CN108220241 B CN 108220241B CN 201711458658 A CN201711458658 A CN 201711458658A CN 108220241 B CN108220241 B CN 108220241B
- Authority
- CN
- China
- Prior art keywords
- erythrocyte
- serum
- medium
- culture medium
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
Abstract
The invention belongs to the field of culture media, and particularly relates to a serum-free culture medium for erythrocyte progenitors, which comprises a basic culture medium and other additive components; the other additive components comprise ITS additive, GlutaMAX, Lipid Concentrate, L-ascorbic acid 2-phosphorylated hemi-magnesium salt hydrate, inorganic salt, lipoic acid, hydrocortisone, stem cell factor, erythropoietin and interleukin-3. The invention has the beneficial effects that: the components in the whole culture medium system are clear, the quality is stable, the erythrocyte progenitor cells in the blood cells are selectively amplified, the erythrocyte progenitor cells can effectively express a specific mark CD71+/CD235a +/-, and the proportion of CD71+/CD235a +/-accounts for about 50-100% on the basis of keeping the original dry characteristic, and the culture medium is suitable for clinical application and scientific research.
Description
Technical Field
The invention belongs to the field of culture media, and particularly relates to a serum-free culture medium for erythrocyte progenitors and a using method thereof.
Background
Induced pluripotent stem cells (ipscs) are an important source of stem cells for replacing embryonic stem cells for the treatment of diseases, the study of embryonic developmental stages and the detection of disease mechanisms. This is particularly important for the study of human embryonic development, disease mechanisms and treatments, since ethical problems involving the use of human embryos are avoided.
Human ipscs (hipscs) were initially generated by overexpressing several transcription factors in dermal fibroblasts (Takahashi et al, 2007; Yu et al, 2007; Park et al, 2008). Like human embryonic stem cells (hescs), hipscs are capable of differentiating into functional cell lineages and thus have great potential for disease models, drug screening, and future therapeutic medicine (Kondo et al, 2013; Park et al, 2008).
Takahashi k1.,et al.,Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell.2007 Nov 30；131(5):861-872.
Yu,J.,et al.,Induced pluripotent stem cell lines derived from human somatic cells.Science.2007；318:1917-1920.
Park IH.,et al.,Reprogramming of human somaic cells to pluripotency with defined factors.Nature.2008；451:141-146.
Recent studies have used human urine samples for the derivation of epithelial-like cells that are capable of reconstituting (reprogrammad) pluripotency (Zhou et al, 2011). This method provides an unlimited source of cells that can be conveniently and non-invasively collected. Nevertheless, this method requires the collection of large volumes of urine samples, leading to problems of logistical difficulties in downstream storage and transport, susceptibility to contamination by microorganisms, etc. (Xue et al, 2013).
Zhou T.,er al.,Generation of induced pluripotent stem cells from urine.J Am Soc Nephrol.2011 Jul；22(7):1221-8.
Xue Y.,et al.,Generating a non-integrating human induced pluripotent Stem cell bank from urine-derived cells.PLoS One.2013 Aug 5；8(8):e70573.
In contrast, peripheral blood T cells are readily obtained from donors and reconstituted with high efficiency (Lohn et al, 2010; Seki et al, 2010; Staerk et al, 2010). However, T cell-derived hipscs carry an existing v (d) J rearrangement on the T Cell Receptor (TCR) gene, and it is not yet clear whether these hipscs can differentiate normally or whether such cells demonstrate a trend towards T cell lymphoma (Serwold et al, 2007).
Loh YH.,et al.,Reprogramming of T cells from human peripheral blood.Cell Stem Cell.2010 Jul 2；7(1):15-9.
Seki T.,et al.,Generation of induced pluripotent stem cells from human terminallydifferentiated circulating T cells.Cell Stem Cell.2010 Jul 2；7(1):11-4.
Staerk J.,et al.,Reprogramming of human peripheral blood cells to induced Pluripotent stem cells.Cell Stem Cell.2010 Jul 2:7(1):20-4.
Serwold T.,er al.,Early TCR expression and aberrant T cell development in mice with endogenous prerearranged T cell receptor genes.J Immunol.2007 Jul 15；179(2):928-38.
Recent studies have reported the reconstitution of non-T cell populations in peripheral blood, (Chou et al, 2011; Mack et al, 2011; Okita et al, 2013), but do not involve the reconstitution of erythroid progenitors, because under normal conditions the number of erythroid progenitors is very small, about 500-1000/ml in peripheral blood, the number in cord blood is about 3.5 times higher, human erythroid progenitors cannot be expanded to some extent, and there are limitations in maintaining dryness and number.
Chou BK.,et al.,Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigeneic and gene expression signatures.Cell Res.2011 Mar；21(3):518-29.
Mack AA.,et al.,Generation of induced pluripotent stem cells from CD34+cells across blood drawn from multiple donors with non-integrating episomal vectors.PLoS One.2011；6(11)；e27956.
Okita K.,er al.,An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells.Stem Cells.2013 Mar；31(3)；458-66.
Disclosure of Invention
In order to solve the above problems, the present invention provides a serum-free culture medium for erythrocyte progenitors, which can selectively and efficiently amplify erythrocyte progenitors in a blood sample.
The invention provides the following technical scheme:
a serum-free culture medium for erythrocyte progenitor cells comprises a basal culture medium and other additives;
the other additive components comprise ITS additive, GlutaMAX, Lipid Concentrate, magnesium sesquimagnesium L-ascorbate 2-phosphate hydrate, inorganic salt, lipoic acid, hydrocortisone, stem cell factor, erythropoietin and interleukin-3.
Preferably, the Basal Medium is selected from any one of Dulbecco's Modified Eagle Medium, Minimum Essential Medium, basic Medium Eagle, Glasgow's Minimum Essential Medium, α Minimum Essential Medium, Iscove's Modified Dulbecco's Medium, F-10, F-12, RPMI1640, and M199.
Preferably, the basic Medium is Iscove's Modified Dulbecco's Medium.
Preferably, the inorganic salt is selected from one or two of ferrous sulfate and ferric nitrate ferrous sulfate.
Preferably, each liter of the amplification medium comprises 1-100ml of ITS additive, 0.1-50ml of GlutaMAX, 0.1-50ml of Lipid Concentrate, 100-300 mu mol of L-ascorbic acid 2-magnesium sesquiphosphate magnesium salt hydrate, 1-5 mu mol of ferrous sulfate, 0.1-2 mu mol of ferric nitrate, 0.1-2 mu mol of lipoic acid, 0.1-2 mu mol of hydrocortisone, 10-200 mu g of dry cell factor, 1-50 mu g of erythropoietin and 31-10 mu g of interleukin.
Preferably, each liter of the amplification medium comprises 2.5-40ml of ITS additive, 0.5-20ml of GlutaMAX, 0.5-10ml of Lipid Concentrate, 150-280 mu mol of L-ascorbic acid 2-magnesium phosphate sesquimagnesium salt hydrate, 2-5 mu mol of ferrous sulfate, 0.1-2 mu mol of ferric nitrate, 0.1-1 mu mol of lipoic acid, 0.3-1.5 mu mol of hydrocortisone, 70-200 mu g of dry cell factor, 5-30 mu g of erythropoietin and 33-10 mu g of interleukin.
The invention also provides a serum-free culture medium for the erythrocyte progenitor cells, which is suitable for the preparation and application of the erythrocyte progenitor cells in human erythrocytes.
The invention also provides a use method of the erythrocyte progenitor cell serum-free medium, which comprises the following steps:
s1, collecting a blood sample;
s2, separating different blood components in the blood sample collected in the S1 by using a gradient centrifugation method to obtain mononuclear cells;
s3, carrying out selective amplification culture on the mononuclear cells obtained in the S2 in an erythrocyte progenitor cell serum-free culture medium to obtain erythrocyte progenitor cells containing a CD71+/CD235a + specific marker.
Preferably, the blood sample is stored at 3 ℃ to 5 ℃ or on ice for less than or equal to 48 hours prior to performing the blood component separation.
Preferably, in the step S3, the selective amplification culture is performed for 6 to 16 days.
Preferably, in the step S3, the erythrocyte progenitors containing the specific marker CD71+/CD235a +/-account for 50-100% of the total number of the erythrocyte progenitors after the expansion culture.
The invention has the beneficial effects that:
exogenous animal-derived components are not introduced into the whole culture medium system, erythrocyte progenitor cells are selectively and efficiently amplified for blood samples with convenient sources, and the effective expression of a specific marker CD71+/CD235a +/-is realized on the basis of keeping the original dry characteristic.
Drawings
FIG. 1 is a graph of the morphology of cells cultured in formula A medium;
FIG. 2A shows the results of a 10-day CD71 expression experiment in formula A medium; wherein the light gray line is the antibody negative control and the black line is the percentage expression of CD71 antibody in the erythrocyte progenitor cells;
FIG. 2B shows the results of a 10-day CD235a expression experiment in formula A medium cultured cells, where the light gray line indicates the antibody negative control and the black line indicates the percentage of CD235a antibody expression in erythrocyte progenitors;
FIG. 3 is a graph of the total cell number obtained after counting the expansion of erythrocyte progenitors after 1 day, 8 days and 16 days of culture in formula A medium and control medium.
Detailed Description
The invention provides a serum-free culture medium for erythrocyte progenitors, which comprises a basic culture medium and other additive components; other additional ingredients include ITS additive, GlutaMAX, Lipid Concentrate, magnesium sesquimagnesium L-ascorbate 2-phosphate hydrate, inorganic salts, lipoic acid, hydrocortisone, stem cell factor, erythropoietin, and interleukin-3.
The erythrocyte progenitor cell serum-free medium can specifically induce and expand erythrocyte progenitor cells from mononuclear cells, and the differentiation and expansion of other cells are inhibited, so that the erythrocyte progenitor cells specifically expressed by CD71+/CD235a +/-can be effectively and massively expanded on the basis of keeping the original dryness characteristics, and the problems of the source and the quantity of the precursor cells reprogrammed by hipscs can be solved.
Blood samples collected by the present invention include human peripheral blood, umbilical cord blood, bone marrow blood, and the like, and the volume of the blood sample used is minute, for example, from about 10 μ l to about 10ml, or any volume falling within this range and greater than 10 ml. Once collected, the blood sample may be stored on ice, or may be refrigerated at a temperature of about 3 ℃ to about 5 ℃ or about 4 ℃. Thus, the sample may be stored on ice for no more than about 8 hours, no more than about 12 hours, no more than about 16 hours, no more than about 20 hours, no more than about 24 hours, no more than about 28 hours, no more than about 32 hours, no more than about 36 hours, no more than about 40 hours, no more than about 44 hours, or no more than about 48 hours. If the sample is to be stored for more than 48 hours, the sample is frozen using liquid nitrogen and stored for future use.
Processing the collected blood sample by using a gradient centrifugation method, separating different blood components, and discarding components such as red blood cells to obtain mononuclear cells; the mononuclear cells include neutrophils, eosinophils, basophils, lymphocytes, erythrocyte progenitors, and the like. Culturing the obtained mononuclear cells with the erythrocyte progenitor cell serum-free medium of the invention is beneficial to the survival of the contained erythrocyte progenitor cells and effectively expands the obtained sufficient cell number to allow the effective induction of pluripotency. The length of the amplification period may vary and amplification may be over a period of no more than 16 days, for example from about 6 to about 14 days. The ratio of CD71+/CD235a +/present in the expanded cell population may be at least half to increase the efficiency of pluripotency induction, e.g., the expanded cell population may contain about 50% or more of CD71+/CD235a +/-, about 75% or more of CD71+/CD235a +/-, about 80% or more of CD71+/CD235a +/-, about 85% or more of CD71+/CD235a +/-, about 90% or more of CD71+/CD235a +/-, about 95% or more of CD71+/CD235a +/-, upon completion of the expansion period. The remaining blood from the sample can be used for other types of analysis, for example, a blood sample remaining after gradient centrifugation can be used for mycoplasma and/or virus screening, and analysis of the blood provides a comprehensive assessment of donor health.
The present invention will be described in detail with reference to the following examples.
The reagents used in the following examples are as follows:
IMDM (basal medium, Thermo fisher), ITS additive (Sigma), GlutaMAX (Thermo fisher), Lipid Concentrate (Thermo fisher), magnesium sesqui-magnesium L-Ascorbate (Mg Ascorbate), ferrous sulfate (FeSO)4) Iron nitrate (Fe (NO)3)3) Lipoic Acid (Lipoic Acid), hydrocortisone (Tocri), stem cell factor SCF (PeproTech), erythropoietin EPO (PeproTech), interleukin-3 IL-3(PeproTech), Stemspan (Stemcell).
Example 1: erythrocyte progenitor cell serum-free medium
IMDM medium (serum-free) was used as the basal medium to which was added a composition selected from the formula in any one of columns A, B, C, D, E in table 2:
TABLE 1 formulation of erythrocyte progenitor cell serum-free medium in different proportions
Example 2 Primary isolation and culture of erythrocyte progenitors
Collecting 10ml adult peripheral blood, transferring into lymphocyte separation tube, centrifuging, and collectingWashing mononuclear cell layer with DPBS twice, sampling, counting, and taking 0.5 × 106Inoculating cells/ml in 6-well plate, dividing into six groups, wherein 5 groups are experimental groups, 1 group is control group, 5 groups are experimental groups, and are added with erythrocyte progenitor cell serum-free culture medium at a ratio shown in Table 1, and control group is added with Stemspan culture medium at 2 ml/well, placing the 6 groups of cells at 37 deg.C and 5% CO2Culturing in an incubator. The 5 experimental groups are respectively supplemented with 2ml of fresh erythrocyte progenitor cell serum-free culture medium on the 4 th day of amplification, the control group is correspondingly added with Stemspan culture medium, the 5 experimental groups are respectively supplemented with 2ml of fresh erythrocyte progenitor cell serum-free culture medium after 2ml of culture medium is discarded on the 8 th day and 12 th day of amplification, and the control group is correspondingly added with Stemspan culture medium.
Example 3 identification of erythrocyte progenitors
As shown in FIG. 1, the change process of the cell morphology of the erythrocyte progenitor cells is observed by a microscope at 1 day, 8 days and 16 days, and the change process is photographed and stored, and the scale bar of the microscope is 200 μm.
As shown in FIG. 2, the expression of surface molecules CD71 and CD235a was detected by flow cytometry at day 10 of erythrocyte progenitor cell culture, and the positive rate and the average fluorescence intensity index were respectively detected.
As shown in FIG. 3, the total cell number obtained after the expansion of the erythrocyte progenitor cells was counted after 1 day, 8 days and 16 days of culture, EP-GM was the erythrocyte progenitor cell culture medium using formulation A in Table 1, and Stemspan was the control group.
As a result: observing the expansion of the separated blood mononuclear cells in an erythrocyte progenitor cell culture medium system by an inverted microscope, wherein the number of erythrocyte progenitor cell colonies is the largest when the blood mononuclear cells are cultured for 7 days, then gradually reducing, indicating that the blood mononuclear cells are in an erythrocyte progenitor cell proliferation stage in 0-7 days, then entering a differentiation stage, and gradually increasing the expression of erythrocyte progenitor cell specific markers CD71+ and CD235+ and increasing the cell number as the culture time is prolonged.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. A serum-free culture medium for erythrocyte progenitors is characterized by comprising a basic culture medium and other additive components;
the basic culture Medium is Iscove's Modified Dulbecco's Medium;
the erythrocyte progenitor cell serum-free medium is prepared from 10ml of ITS additive, 10ml of GlutaMAX, 1ml of Lipid Concentrate, 250 mu mol of L-ascorbic acid 2-magnesium phosphate sesquimagnesium salt hydrate, 3 mu mol of ferrous sulfate, 0.2 mu mol of ferric nitrate, 1 mu mol of lipoic acid, 1 mu mol of hydrocortisone, 100 mu g of dry cell factor SCF, 20 mu g of erythropoietin EPO and 35 mu g of interleukin, and is supplemented to one liter by using a basic medium.
2. Use of the serum-free medium for erythrocyte progenitors of claim 1 in the preparation of human erythrocyte progenitors.
3. A method of using the serum-free medium for erythrocyte progenitors according to claim 1, wherein the method comprises:
s1, collecting a blood sample;
s2, separating different blood components in the blood sample collected in the S1 by using a gradient centrifugation method to obtain mononuclear cells;
s3, carrying out selective amplification culture on the mononuclear cells obtained in the S2 in an erythrocyte progenitor cell serum-free culture medium to obtain the cell containing CD71+/CD235a+Specifically labeled erythrocyte progenitors.
4. The method of claim 3, wherein the blood sample is stored on ice at 3 ℃ to 5 ℃ for less than or equal to 48 hours before being subjected to blood component separation.
5. The method for using serum-free medium for erythrocyte progenitors according to claim 3 or 4, wherein the selective expansion culture in S3 step lasts 6-16 days.
6. The method for using the serum-free medium for erythrocyte progenitors according to claim 3 or 4, wherein the step S3 comprises CD71+/CD235a+/-The erythrocyte progenitor cells with the specific markers account for 50-100% of the total number of the erythrocyte progenitor cells after the amplification culture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711458658.7A CN108220241B (en) | 2017-12-28 | 2017-12-28 | Erythrocyte progenitor cell serum-free medium and use method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711458658.7A CN108220241B (en) | 2017-12-28 | 2017-12-28 | Erythrocyte progenitor cell serum-free medium and use method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108220241A CN108220241A (en) | 2018-06-29 |
| CN108220241B true CN108220241B (en) | 2021-02-09 |
Family
ID=62645666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711458658.7A Active CN108220241B (en) | 2017-12-28 | 2017-12-28 | Erythrocyte progenitor cell serum-free medium and use method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108220241B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981446A4 (en) * | 2019-06-10 | 2023-07-12 | I Peace, Inc. | Red blood cell removal device, mononuclear cell collector, cell culture device, cell culture system, cell culture method, and mononuclear cell collection method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038664A1 (en) * | 2005-09-27 | 2007-04-05 | Massachusetts Institute Of Technology | In vitro erythroid micronucleus assay for genotoxicity |
| CN105838675A (en) * | 2016-06-07 | 2016-08-10 | 广东万海细胞生物科技有限公司 | Hematopoietic stem cell serum-free culture medium |
| CN107201338A (en) * | 2016-03-16 | 2017-09-26 | 华南生物医药研究院 | Induction of hematopoiesis stem/progenitor cells breed the method and its application with erythroid differentiation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012020958A2 (en) * | 2010-02-22 | 2015-09-15 | Univ Paris Curie | "Culture medium for the rearing and / or differentiation of hemapo lineage cells |
| US20180135012A1 (en) * | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| CN107338220A (en) * | 2017-06-07 | 2017-11-10 | 北京呈诺医学科技有限公司 | The method and its culture medium that inductive pluripotent stem cells break up to candidate stem cell |
-
2017
- 2017-12-28 CN CN201711458658.7A patent/CN108220241B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038664A1 (en) * | 2005-09-27 | 2007-04-05 | Massachusetts Institute Of Technology | In vitro erythroid micronucleus assay for genotoxicity |
| CN107201338A (en) * | 2016-03-16 | 2017-09-26 | 华南生物医药研究院 | Induction of hematopoiesis stem/progenitor cells breed the method and its application with erythroid differentiation |
| CN105838675A (en) * | 2016-06-07 | 2016-08-10 | 广东万海细胞生物科技有限公司 | Hematopoietic stem cell serum-free culture medium |
Non-Patent Citations (2)
| Title |
|---|
| In vitro proliferation, expansion, and differentiation of a CD34+ cell-enriched hematopoietic cell population from cytokines;Patricia Flores-Guzman 等;《Archives of medical research》;20010622;第33卷(第2期);第107-114页 * |
| 诱导脐带血造血干/祖细胞分化为红系祖细胞及其规模化扩增;王金明;《中国优秀硕士学位论文全文数据库（电子期刊）医药卫生科技辑》;20140515(第5期);第7页第2.1节、第9页第2.1.1.3节、第11页第2段、第17页第3段、第24页第2.2.2.3节及表2-2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108220241A (en) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11732242B2 (en) | Automated system for producing induced pluripotent stem cells or differentiated cells | |
| CN109722415B (en) | Hematopoietic stem cell culture composition, culture medium and hematopoietic stem cell culture method | |
| Guan et al. | Isolation and cultivation of stem cells from adult mouse testes | |
| Mauro et al. | Isolation, characterization, and in vitro differentiation of ovine amniotic stem cells | |
| CN108350429A (en) | For the method by multipotential stem cell directed differentiation for immunocyte | |
| Ferrari et al. | Isolation of neural stem cells from neural tissues using the neurosphere technique | |
| Wang et al. | Derivation of neural stem cells from human adult peripheral CD34+ cells for an autologous model of neuroinflammation | |
| Hertsenberg et al. | Generation of corneal keratocytes from human embryonic stem cells | |
| Tosoni et al. | Functional purification of human and mouse mammary stem cells | |
| CN108220241B (en) | Erythrocyte progenitor cell serum-free medium and use method thereof | |
| CN112708596A (en) | Detection method for in-vitro inhibition of lymphocyte proliferation by mesenchymal stem cells | |
| CN103540566A (en) | Methods and compositions for long term hematopoietic repopulation | |
| Dey et al. | Sca-1+ cells from fetal heart with high aldehyde dehydrogenase activity exhibit enhanced gene expression for self-renewal, proliferation, and survival | |
| KR102142254B1 (en) | Method for improving separation efficiency of urine stem cells using 3,4'-dihydroxyflavones and promoting hematopoietic stem cell differentiation efficiency of urine stem cell-derived pluripotent stem cells | |
| WO2009151844A1 (en) | Multipotent stem cell cultures | |
| Arzt et al. | Chemically Defined Production of Tri‐Lineage Human iPSC‐Derived Cardiac Spheroids | |
| CN110592007B (en) | Mesenchymal stem cell and preparation method and application thereof | |
| Kovarova et al. | Differentiation of mast cells from embryonic stem cells | |
| Chen et al. | Derivation of Transgene‐Free Induced Pluripotent Stem Cells from a Single Drop of Blood | |
| Morton et al. | Isolation of Extracellular Vesicles from Subventricular Zone Neural Stem Cells | |
| US11365390B2 (en) | Methods of modulating cell phenotype by way of regulating the gaseous environment | |
| WO2020010657A1 (en) | T cell culture medium and culture method | |
| CN114269900A (en) | Method for enriching cardiac muscle cells | |
| Deslauriers et al. | Modeling leukemia stem cells with patient-derived induced pluripotent stem cells | |
| WO2023136691A1 (en) | Method for increasing exosome productivity and composition comprising exosomes produced thereby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |